NCT00334074View on ClinicalTrials.gov

Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

February 28, 2007

Study Completion Date

February 29, 2008

Conditions
Acute Myelogenous LeukemiaMyelodysplastic SyndromesChronic Myelogenous Leukemia
Interventions
DRUG

Clofarabine and Cytarabine

Phase II Trial of Clofarabine and Cytarabine in Relapsed Standard-Risk AML and Untreated High-Risk MDS in Adult Patients, and Untreated AML in selected Elderly Patients at high risk of anthracycline toxicity

Trial Locations (1)

75246

Baylor University Medical Center, Dallas

Sponsors
All Listed Sponsors
lead

Baylor Research Institute

OTHER